Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PRINCETON, N.J. (BUSINESS WIRE) $BMY #CRC Bristol Myers Squibb (NYSE: BMY) today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients whose disease has progres.
Bristol Myers Squibb today announced that the Phase 3 RELATIVITY-123 trial evaluating the fixed-dose combination of nivolumab and relatlimab for the treatment of microsatellite stable metastatic.
Doctors on Friday cautioned the use of Meftal among children, pregnant and lactating women, after the Indian Pharmacopoeia Commission (IPC) issued an alert against the drug. Meftal is commonly used as a painkiller for menstrual cramps, rheumatoi
The Indian Pharmacopoeia Commission s advisory alerts users about Meftal s dangers, specifically its active ingredient mefenamic acid, linked to severe allergic reactions like DRESS syndrome. This syndrome, a type 4 hypersensitivity reaction, causes skin issues, fever, and organ abnormalities. Meftal s risks extend to stomach ulcers, bleeding, and kidney problems with prolonged use. Users are urged to consult doctors, avoid self-medication, and prioritize safety, emphasizing informed decision-making when considering this widely used painkiller.